Across TCGA pan-cancer cohorts, ZBED6CL Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBED6CL data layer compared with 24 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZBED6CL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBED6CL expression acts as an unfavorable survival marker.

SCLC, UCEC, and SKCM are the cancer types where ZBED6CL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	II,III,IV	0.202	0.731	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZBED6CL tumor-vs-normal RNA expression · all ZBED6CL data types